. Author manuscript; available in PMC: 2021 Dec 15.

Published in final edited form as: J Acquir Immune Defic Syndr. 2020 Dec 15;85(5):651–658. doi: 10.1097/QAI.0000000000002502

Table 2.

PK parameters for TFV after co-administration with LDMTX. Data represent Geometric mean (GM) with 90% CIs, except for geometric mean ratio (GMR) of LDMTX/placebo.

	LDMTX (n=20)	Placebo (n=28)	LDMTX/Placebo
	GM (90% CI)	GM (90% CI)	GMR (90% CI)	p-value
AUC₆ (ng•h/mL)	967 (802, 1166)	1239 (1105, 1390)	0.78 (0.64, 0.96)	0.06
PI-based ART	1275 (874, 1859)	1343 (1127, 1600)	0.95 (0.68, 1.32)	0.80
Non-PI-based ART	882 (706, 1101)	1167 (992, 1372)	0.76 (0.58, 0.98)	0.08
AUC₂₄ (ng•h/mL)^*	2235 (1511, 3306)	3481 (2948, 4110)	0.64 (0.45, 0.91)	0.08
AUC_24i (ng•h/mL)	2647 (2218, 3160)	3503 (3087, 3975)	0.76 (0.61, 0.93)	0.033
PI-based ART	3331 (2202,5039)	3873 (3205, 4679)	0.86 (0.60, 1.23)	0.52
Non-PI-based ART	2453 (1995, 3014)	3249 (2718, 3883)	0.75 (0.58, 0.98)	0.08
C_max (ng/mL)	231 (188, 283)	315 (284, 349)	0.73 (0.60, 0.90)	0.027
PI-based ART	314 (234,420)	341 (291, 400)	0.92 (0.69, 1.22)	0.62
Non-PI-based ART	209 (162, 268)	296 (256, 343)	0.70 (0.53, 0.93)	0.045
C_min (ng/mL)	43 (24, 79)	63 (41, 97)	0.69 (0.34, 1.40)	0.39
PI-based ART	70 (45, 110)	51 (18, 146)	1.37 (0.27, 6.93)	0.62
Non-PI-based ART	37 (16, 82)	73 (58, 92)	0.50 (0.23, 1.11)	0.17

n=7 for LDMTX and 10 for placebo. AUC, area under concentration-time curve, AUC_24i, AUC from 0 to 24 h with imputed 24 h concentration from 0 h, PI, protease inhibitor.